In-silico Studies of Heterocyclic Benzoxazole Derivatives as an Anticancer Agent: Molecular Docking, 2D and 3D QSAR
Abstract
In-silico molecular docking studies and QSAR study of benzoxazole derivatives synthesized by Kakkar et al. was done. Comparative studies of docking of 5-flurouracil and 20 compounds revealed presence of considerable interactions which indicates the affinity of newly synthesized compounds for thymidylate synthase. The statistically significant 2D-QSAR models were developed using molecular design suite (VLifeMDS 4.6). The study was performed with 20 compounds (data set) using sphere exclusion (SE) algorithm, random selection and manual selection methods used for the division of the data set into training and test set. Multiple linear regression [MLR] methodology with stepwise (SW) forward-backward variable selection method was used for building the QSAR models. The results of the 2D-QSAR models were further compared with 3D-QSAR models generated by kNN-MFA, (k-Nearest Neighbor Molecular Field Analysis) investigating the substitutional requirements for the favourable anticancer activity against HCT 116 cell line and providing useful information in the characterization and differentiation of their binding sites. The results derived may be useful for further designing of benzoxazole derivatives as anticancer agents prior to synthesis.
Keywords:
Benzoxazole, docking, thymidylate synthase, 2D QSAR, 3D QSAR, Anticancer, MLR, kNN MFA.DOI
https://doi.org/10.25004/IJPSDR.2023.150612References
The Global Burden of Disease: 2004 Update; World Health Organization: Geneva, Switzerland, 2008.
Wang Z, Shi XH, Wang J, Zhou T, Xu YZ, Huang TT, Li YF, Zhao YL, Yang L, Yang S. Synthesis, Structure-Activity Relationships and Preliminary Antitumor Evaluation of Benzothiazole-2-thiol Derivatives as Potential Anticancer Agents. Bioorg. Med. Chem. Lett. 2011; 21:1907–1101.
Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. Global cancer facts & figures. American Cancer Society. 2007.
Hanahan D, Weinberg RA. The Hallmarks of cancer. Cell. 2000; 100: 57.
Stratton MR, Campbell PJ, Futreal PA. The Cancer Genome. Nature. 2009; 458: 719.
Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011; 144: 646.
Boyle FT, Costello GF, Cancer therapy: A Move to the Molecular Level. Chem Soc Rev. 1998; 27: 251.
Gibbs JB, Mechanism-based Target Identification and Drug Discovery in Cancer Research. Science. 2000; 287: 1969.
Lu Y, Chen YJ, Xiao M, Li W, Miller DD. An Overview of Tubulin Inhibitors that Interact with the Colchicine Binding Site. Pharm Res. 2012; 29: 2943.
Don MJ, Shen CC, Lin YL, Syu WJ, Ding YH, Sun CM. Nitrogen Containing Compounds from Salvia Miltiorrhiza. Nat Prod. 2005; 68: 1066.
Viirre RD, Evindar G, Batey RA. Copper-catalyzed Domino Annulation Approaches to the Synthesis of Benzoxazoles under Microwave-accelerated and Conventional Thermal Conditions. J Org Chem. 2008; 73: 345.
Osmaniye D, Çelikateş BK, Saglık BN,Levent S,Cevik UA,Cavusoglu BK, Ilgın S, Ozkay Y,Kaplancıkli ZA. Synthesis of some New Benzoxazole Derivatives and Investigation of their Anticancer Activities. Eur J Med Chem. 2021; 210: 112979.
Cheng CC, Liu DE, Chou TC. Design of Antineoplastic Agents on the Basis of the "2-Phenylnaphthalene-Type" Structural Pattern. I. Synthesis of Substituted 3- Phenylquinazolones, Benzoxazolo[2,3-b]quinazolones and Benzothiazolo[2,3- b]quinazolones. Heterocycles. 1993; 35: 775.
Elnima EI, Zubair MU, Al-Badr AA. Antibacterial and antifungal activities of benzimidazole and benzoxazole derivatives. Antimicrobial Agents and Chemotherapy, 1981; 19: 29-32.
Kaplancikli Z. A, Turan-Zitouni G, Revial G, Guven K. Synthesis and Study of Antibacterial and Antifungal Activities of Novel 2-[[(benzoxazole/benzimidazole-2- yl)sulfanyl] acetylamino]thiazoles. Archives of Pharmacal. Research. 2004; 27: 1081–1085.
Sun LQ, Chen J, Bruce M, Deskus JA, Epperson JR, Takaki K, Johnson G, Iben L, Mahle C. D, Ryan E, Xu C. Synthesis and Structure-activity Relationship of Novel Benzoxazole Derivatives as Melatonin Receptor Agonists. Bioorg. Med. Chem. Lett. 2004; 14: 3799.
Ertan T, Yildiz I, Tekiner-Gulbas B, Bolelli K, Temiz-Arpaci O, Yalcin I, Aki E, Ozkan S, Kaynak F. Synthesis, biological evaluation and 2D-QSAR analysis of benzoxazoles as antimicrobial agents. Eur. J Med. Chem. 2000; 44: 501.
Alper-Hayta S, Arisoy M, Temiz-Arpaci O, Yildiz I, Aki E, Oezkan S, Kaynak F. Synthesis and Anticancer Activity of New ((Furan-2-yl)-1,3,4-thiadiazolyl)-1,3,4- oxadiazole Acyclic Sugar Derivatives. Eur. J Med. Chem. 2008; 43: 2568.
Sun A, Prussia A, Zhan W, Murray EE, Doyle J, Cheng LT, Yoon JJ, Radchenko EV, Palyulin VA, Compans RW, Liotta DC, Plemper RK, Snyder JA. Nonnucleoside Inhibitor of Measles Virus RNA-Dependent RNA Polymerase Complex Activity. J Med. Chem. 2006; 49: 5080.
Borrel C, Thoret S, Cachet X, Guenard D, Tillequin F, Koch M, Michel S. New antitubulin derivatives in the combretastatin A4 series: synthesis and biological evaluation. Bioorg. Med. Chem. 2005; 13: 3853.
Katritzky A. QSAR modeling, synthesis, and bioassay of diverse leukemia RPMI-8226 cell line active agents. Bioorg. Med. Chem. Lett. 2010; 45: 5183-99.
Rapatri V, Chitre T, Bothara K. Novel 4-(morpholin-4-yl)-N- (arylidene) Benzohydrazides: Synthesis, Antimycobacterial activity, and QSAR Investigations. Eur. J Med. Chem. 2009; 44: 3954-60.
Kakkar S, Kumar S, Narasimhan B, Lim S. M, Ramasamy K, Mani V, Ali Shah S. A. Design, Synthesis, and Biological Potential of Heterocyclic Benzoxazole Scafolds as Promising Antimicrobial and Anticancer Agents. Chemistry Central Journal. 2018; 12: 96.
Sastry MG, Adzhigirey M, Day T, Annabhimoju R, Sherman W. Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments. J. Comput. Aided Mol. Des. 2013; 27(3): 221-234.
Kumar S, Singh J, Narasimhan B, Shah S.A.A, Lim S.M, Ramasamy K, Mani V. Reverse Pharmacophore Mapping and Molecular Docking Studies for Discovery of GTPase HRas as Promising Drug Target for Bis-pyrimidine Derivatives. Chem. Cent. J. 2018; 12: 106.
Katritzky A. QSAR modeling, synthesis, and bioassay of diverse leukemia RPMI-8226 cell line active agents. Bioorg. Med. Chem. Lett. 2010; 45: 5183-99.
Rapatri V, Chitre T,Bothara K. Novel 4-(morpholin-4-yl)-N- (arylidene) benzohydrazides: Synthesis, Antimycobacterial Activity, and QSAR Investigations. Eur. J Med. Chem. 2009; 44: 3954-60.
Karthiga S, Velmurugan D. Molecular modeling, QSAR and pharmacophore studies on anti-viral, anti-malarial and anti-inflammatory bioactive compounds from marine sources. Asian J Pharma Clin Res. 2015; 8: 36-43.
VLife Molecular Design Suite version 3.5; VLife Sciences Technologies Pvt. Ltd., Pune, India; 2010.
Sharma V, Sharma P.C, Kumar V. In silico Molecular Docking Analysis of Natural Pyridoacridines as Anticancer Agents. Adv. Chem. 2016; 1-9.
Hansch C, Fujita T. p-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964; 86(8): 1616-1626.
Life Molecular Design Suite 3.0, VLife Sciences Technologies Pvt. Ltd; Baner Road: Pune, Maharashtra, India. www.Vlifescien ces.com. Accessed Jan 2019
Nandi S, Bagchi M. 3D-QSAR and Molecular Docking Studies of 4-anilinoquinazoline Derivatives: A Rational Approach to Anticancer Drug Design. Mol Divers. 2010, 14, 27.
Bora P, Kumar A, Kumar Singh A, Singh H, Narasimhan B, Kumar P. Molecular Docking and QSAR Studies of Indole Derivatives as Antifungal Agents. Cur. Chinese Chemistry. 2023; 3:1-12.
Ou-Yang S, Lu J, KongX, Liang Z, Luo C, Jiang H. Computational drug discovery. Acta Pharmacol. Sin.2012; 33(9): 1131-1140.
Habeeb AG, Parveen P, Knaus EE. Design and Synthesis of 4, 5-diphenyl-4-isoxazolines: Novel Inhibitors of Cylooxygenase-2 with Analgesic and Anti-Inflammatory Activity. J Med. Chem. 2001; 44: 2921-7.
Palomer A, Perez J. J, Navea S, Llorens O, Pascual J, Garcia L. ModelingCyclooxygenase Inhibition: Implication of active site Hydration on the Selectivity of Ketoprofen Analogues. J Med. Chem. 2000; 43: 2280-4.
Price ML, Jorgensen WL. Analysis of Binding Affinities for Celecoxib Analogues with COX-1 and COX-2 from Combined Docking and monte carloSimulations and Insight into the COX-2/COX-1 Selectivity. J Am. Chem. Soc. 2000; 94: 55-66.
Price ML, Jorgensen WL. The Rationale for the Observed COX-2/COX-1 Selectivity of Celecoxib from Monte Carlo Simulation. Bioorg. Med. Chem. Lett. 2001; 11:1541-4.
Published
Abstract Display: 521 
PDF Downloads: 367 
